SCHEMBL997469

SCHEMBL997469

Cc1cc(C)cc(NC(=O)N2CCc3c([nH]c4nccnc34)C2c2cccc(F)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.49
LHCGR P22888 2/20 0.45
POLB P06746 2/20 0.45
TP53 P04637 4/20 0.44
MAPT P10636 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047389 0.90 KIF11 (0.51) KIF11LHCGRPOLBTP53MAPT
SCHEMBL997779 0.89 KIF11 (0.50) KIF11LHCGRPOLBTP53MAPT
SCHEMBL998701 0.85 KIF11 (0.50) KIF11TP53MAPT
SCHEMBL2030009 0.85 KIF11 (0.50) KIF11LHCGRPOLBTP53MAPT
SCHEMBL998559 0.85 KIF11 (0.48) KIF11LHCGRPOLBTP53MAPT
SCHEMBL998071 0.84 KIF11 (0.53) KIF11LHCGRPOLBTP53MAPT
SCHEMBL998307 0.84 KIF11 (0.55) KIF11LHCGRPOLBTP53MAPT
SCHEMBL998540 0.84 KIF11 (0.51) KIF11LHCGRPOLBTP53MAPT
SCHEMBL999680 0.84 LHCGR (0.38) KIF11LHCGRTP53
SCHEMBL998501 0.84 KIF11 (0.49) KIF11TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed
EP-1637521-A1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS KIF11 4760/4885LHCGR 1338/4885POLB 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.